CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving CCI-779 together with rituximab works in
treating patients with relapsed or refractory mantle cell lymphoma. Drugs used in
chemotherapy, such as CCI-779, work in different ways to stop the growth of cancer cells,
either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as
rituximab, can block cancer growth in different ways. Some block the ability of cancer cells
to grow and spread. Others find cancer cells and help kill them or carry cancer-killing
substances to them. Giving CCI-779 together with rituximab may kill more cancer cells